Cefepime-induced神经毒性

Q4 Nursing Journal of Neurocritical Care Pub Date : 2019-12-24 DOI:10.18700/jnc.190109

Se-Jin Lee

{"title":"Cefepime-induced神经毒性","authors":"Se-Jin Lee","doi":"10.18700/jnc.190109","DOIUrl":null,"url":null,"abstract":"Cefepime, a fourth-generation cephalosporin antibiotic, was approved for use in 1996. It is widely used to treat severe bacterial infections because it acts against both gram-negative and gram-positive bacterial strains, and has antipseudomonal activity. Safety data of cefepime in clinical trials were relatively favorable when initially approved. Approximately 3% of 2,032 patients treated with cefepime experienced adverse central nervous system (CNS) effects including headache (2.4%), dizziness (0.7%), and Cefepime-induced neurotoxicity","PeriodicalId":33246,"journal":{"name":"Journal of Neurocritical Care","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":"{\"title\":\"Cefepime-induced neurotoxicity\",\"authors\":\"Se-Jin Lee\",\"doi\":\"10.18700/jnc.190109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cefepime, a fourth-generation cephalosporin antibiotic, was approved for use in 1996. It is widely used to treat severe bacterial infections because it acts against both gram-negative and gram-positive bacterial strains, and has antipseudomonal activity. Safety data of cefepime in clinical trials were relatively favorable when initially approved. Approximately 3% of 2,032 patients treated with cefepime experienced adverse central nervous system (CNS) effects including headache (2.4%), dizziness (0.7%), and Cefepime-induced neurotoxicity\",\"PeriodicalId\":33246,\"journal\":{\"name\":\"Journal of Neurocritical Care\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-12-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"14\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neurocritical Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18700/jnc.190109\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Nursing\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurocritical Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18700/jnc.190109","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Nursing","Score":null,"Total":0}

引用次数: 14

摘要

头孢吡肟是第四代头孢菌素类抗生素，于1996年获批使用。它被广泛用于治疗严重的细菌感染，因为它对革兰氏阴性和革兰氏阳性菌株都有作用，并具有抗假单胞菌活性。在最初批准时，头孢吡肟在临床试验中的安全性数据相对较好。2032名接受头孢吡肟治疗的患者中约有3%出现中枢神经系统不良反应，包括头痛(2.4%)、头晕(0.7%)和头孢吡肟诱导的神经毒性

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Cefepime-induced neurotoxicity

Cefepime, a fourth-generation cephalosporin antibiotic, was approved for use in 1996. It is widely used to treat severe bacterial infections because it acts against both gram-negative and gram-positive bacterial strains, and has antipseudomonal activity. Safety data of cefepime in clinical trials were relatively favorable when initially approved. Approximately 3% of 2,032 patients treated with cefepime experienced adverse central nervous system (CNS) effects including headache (2.4%), dizziness (0.7%), and Cefepime-induced neurotoxicity

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊